Stock Track | GeneDx Soars Over 25% Pre-Market on Q4 Beat, Robust 2025 Revenue Guidance

Stock Track
02-18

GeneDx Holdings Corp (WGS) stock surged over 25% in pre-market trading on Tuesday, following the company's robust fourth-quarter 2024 results and upbeat fiscal 2025 revenue guidance.

For the fourth quarter of 2024, GeneDx reported revenue of $95.3 million, significantly exceeding analysts' estimates of $82.23 million. The strong revenue growth was primarily driven by a 101% year-over-year increase in exome and genome test revenue to $78.8 million.

The company's adjusted net income for the quarter stood at $16.8 million, substantially higher than analysts' expectations of $2.9 million. GeneDx's adjusted gross margin expanded to 70%, up from 56% in the prior-year quarter, reflecting the company's operational efficiencies and increasing contribution from higher-margin exome and genome testing.

Looking ahead, GeneDx provided an optimistic revenue guidance for the full year 2025, forecasting revenues in the range of $350 million to $360 million. This guidance exceeds analysts' consensus estimate of $338.8 million and represents growth in exome/genome volume and revenue of at least 30% compared to 2024.

The company's strong performance and robust outlook can be attributed to several factors, including the growing adoption of exome and genome sequencing by state Medicaid programs, the launch of new products like ultraRapid Whole Genome Sequencing, and strategic partnerships to expand its reach and capabilities.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10